Notes
Notes - notes.io |
Combinatorial invariant for Morse-Smale diffeomorphisms in surfaces with orientable heteroclinic.
This study compared the measurements of total steps and moderate-to-vigorous physical activity (MVPA) between ActiGraph and the Lifecorder and Active Style Pro accelerometers in junior high school students.
The total steps and MVPA significantly differed between ActiGraph and Lifecorder measurements, whereas the intraclass correlation coefficients (ICCs) for total steps and MVPA between the two accelerometers were not significant. There was no significant difference between the total steps measured using ActiGraph and Active Style Pro, and moderate agreement was noted. Additionally, MVPA measured using ActiGraph and Active Style Pro significantly differed, whereas the ICC for MVPA measured using the two accelerometers was not significant. When comparing the total steps between ActiGraph and Lifecorder and MVPA between ActiGraph and Lifecorder or Active Style Pro, it should be noted that the accelerometer measurements are not compatible.
The total steps and MVPA significantly differed between ActiGraph and Lifecorder measurements, whereas the intraclass correlation coefficients (ICCs) for total steps and MVPA between the two accelerometers were not significant. There was no significant difference between the total steps measured using ActiGraph and Active Style Pro, and moderate agreement was noted. Additionally, MVPA measured using ActiGraph and Active Style Pro significantly differed, whereas the ICC for MVPA measured using the two accelerometers was not significant. When comparing the total steps between ActiGraph and Lifecorder and MVPA between ActiGraph and Lifecorder or Active Style Pro, it should be noted that the accelerometer measurements are not compatible.An amendment to this paper has been published and can be accessed via the original article.
Radiotherapy for breast cancer (BC) and its resulting cardiac exposure are associated with subclinical left ventricular dysfunction characterized by early decrease of global longitudinal strain (LS) measurement based on 2D speckle-tracking echocardiography. Recent software allows multi-layer and segmental analysis of strain, which may be of interest to quantify and locate the impact of cardiac exposure on myocardial function and potentially increase the early detection of radiation-induced cardiotoxicity. The aim of the study was to evaluate whether decrease in LS 6 months after radiotherapy is layer-specific and if it varies according to the left ventricular regional level and the coronary arterial territories.
LS was measured at baseline before radiotherapy and 6 months post-radiotherapy. The LS was obtained for each myocardial layer (endocardial, mid-myocardial, epicardial), left ventricular regional level (basal, mid, apical) and coronary artery territory (left anterior descending artery (LAD), circumhe endocardial layer-based LS might be the most sensitive parameter.
ClinicalTrials.gov NCT02605512 , Registered 6 November 2015 - Retrospectively registered.
ClinicalTrials.gov NCT02605512 , Registered 6 November 2015 - Retrospectively registered.
Although metabolic associate fatty liver disease (MAFLD) is associated with obesity, it can also occur in lean patients. selleck chemical MAFLD is more aggressive in lean patients compared to obese patients, with a higher risk of mortality. Specific biomarkers to diagnose differentially lean or overweight MAFLD are missing. Histones and nucleosomes are released in the bloodstream upon cell death. Here, we propose a new, fast, imaging and epigenetics based approach to investigate the severity of steatosis in lean MAFLD patients.
A total of 53 non-obese patients with histologically confirmed diagnosis of MAFLD were recruited. Twenty patients displayed steatosis grade 1 (0-33%), 24 patients with steatosis grade 2 (34-66%) and 9 patients with steatosis grade 3 (67-100%). The levels of circulating nucleosomes were assayed using enzyme-linked immunosorbent assay, while individual histones or histone dimers were assayed in serum samples by means of a new advanced flow cytometry ImageStream(X)-adapted method. Circulating nucleosome levels associated poorly with MAFLD in the absence of obesity. We implemented successfully a multi-channel flow methodology on ImageStream(X), to image single histone staining (H2A, H2B, H3, H4, macroH2A1.1 and macroH2A1.2). We report here a significant depletion of the levels of histone variants macroH2A1.1 and macroH2A1.2 in the serum of lean MAFLD patients, either individually or in complex with H2B.
In summary, we identified a new circulating histone signature able to discriminate the severity of steatosis in individuals with lean MAFLD, using a rapid and non-invasive ImageStream(X)-based imaging technology.
In summary, we identified a new circulating histone signature able to discriminate the severity of steatosis in individuals with lean MAFLD, using a rapid and non-invasive ImageStream(X)-based imaging technology.
Multiple myeloma (MM) patients with high cytogenetic risk have poor outcomes. In CASTOR, daratumumab plus bortezomib/dexamethasone (D-Vd) prolonged progression-free survival (PFS) versus bortezomib/dexamethasone (Vd) alone and exhibited tolerability in patients with relapsed or refractory MM (RRMM).
This subgroup analysis evaluated D-Vd versus Vd in CASTOR based on cytogenetic risk, determined using fluorescence in situ hybridization and/or karyotype testing performed locally. High-risk patients had t(4;14), t(14;16), and/or del17p abnormalities. Minimal residual disease (MRD; 10
sensitivity threshold) was assessed via the clonoSEQ® assay V2.0. Of the 498 patients randomized, 40 (16%) in the D-Vd group and 35 (14%) in the Vd group were categorized as high risk.
After a median follow-up of 40.0 months, D-Vd prolonged median PFS versus Vd in patients with standard (16.6 vs 6.6 months; HR, 0.26; 95% CI, 0.19-0.37; P < 0.0001) and high (12.6 vs 6.2 months; HR, 0.41; 95% CI, 0.21-0.83; P = 0.0106) cytogenetic risk. D-Vd achieved deep responses, including higher rates of MRD negativity and sustained MRD negativity versus Vd, regardless of cytogenetic risk. The safety profile was consistent with the overall population of CASTOR.
These updated data reinforce the effectiveness and tolerability of daratumumab-based regimens for RRMM, regardless of cytogenetic risk status.
ClinicalTrials.gov, NCT02136134 . Registered 12 May 2014.
ClinicalTrials.gov, NCT02136134 . Registered 12 May 2014.
Read More: https://www.selleckchem.com/products/FK-506-(Tacrolimus).html
This study compared the measurements of total steps and moderate-to-vigorous physical activity (MVPA) between ActiGraph and the Lifecorder and Active Style Pro accelerometers in junior high school students.
The total steps and MVPA significantly differed between ActiGraph and Lifecorder measurements, whereas the intraclass correlation coefficients (ICCs) for total steps and MVPA between the two accelerometers were not significant. There was no significant difference between the total steps measured using ActiGraph and Active Style Pro, and moderate agreement was noted. Additionally, MVPA measured using ActiGraph and Active Style Pro significantly differed, whereas the ICC for MVPA measured using the two accelerometers was not significant. When comparing the total steps between ActiGraph and Lifecorder and MVPA between ActiGraph and Lifecorder or Active Style Pro, it should be noted that the accelerometer measurements are not compatible.
The total steps and MVPA significantly differed between ActiGraph and Lifecorder measurements, whereas the intraclass correlation coefficients (ICCs) for total steps and MVPA between the two accelerometers were not significant. There was no significant difference between the total steps measured using ActiGraph and Active Style Pro, and moderate agreement was noted. Additionally, MVPA measured using ActiGraph and Active Style Pro significantly differed, whereas the ICC for MVPA measured using the two accelerometers was not significant. When comparing the total steps between ActiGraph and Lifecorder and MVPA between ActiGraph and Lifecorder or Active Style Pro, it should be noted that the accelerometer measurements are not compatible.An amendment to this paper has been published and can be accessed via the original article.
Radiotherapy for breast cancer (BC) and its resulting cardiac exposure are associated with subclinical left ventricular dysfunction characterized by early decrease of global longitudinal strain (LS) measurement based on 2D speckle-tracking echocardiography. Recent software allows multi-layer and segmental analysis of strain, which may be of interest to quantify and locate the impact of cardiac exposure on myocardial function and potentially increase the early detection of radiation-induced cardiotoxicity. The aim of the study was to evaluate whether decrease in LS 6 months after radiotherapy is layer-specific and if it varies according to the left ventricular regional level and the coronary arterial territories.
LS was measured at baseline before radiotherapy and 6 months post-radiotherapy. The LS was obtained for each myocardial layer (endocardial, mid-myocardial, epicardial), left ventricular regional level (basal, mid, apical) and coronary artery territory (left anterior descending artery (LAD), circumhe endocardial layer-based LS might be the most sensitive parameter.
ClinicalTrials.gov NCT02605512 , Registered 6 November 2015 - Retrospectively registered.
ClinicalTrials.gov NCT02605512 , Registered 6 November 2015 - Retrospectively registered.
Although metabolic associate fatty liver disease (MAFLD) is associated with obesity, it can also occur in lean patients. selleck chemical MAFLD is more aggressive in lean patients compared to obese patients, with a higher risk of mortality. Specific biomarkers to diagnose differentially lean or overweight MAFLD are missing. Histones and nucleosomes are released in the bloodstream upon cell death. Here, we propose a new, fast, imaging and epigenetics based approach to investigate the severity of steatosis in lean MAFLD patients.
A total of 53 non-obese patients with histologically confirmed diagnosis of MAFLD were recruited. Twenty patients displayed steatosis grade 1 (0-33%), 24 patients with steatosis grade 2 (34-66%) and 9 patients with steatosis grade 3 (67-100%). The levels of circulating nucleosomes were assayed using enzyme-linked immunosorbent assay, while individual histones or histone dimers were assayed in serum samples by means of a new advanced flow cytometry ImageStream(X)-adapted method. Circulating nucleosome levels associated poorly with MAFLD in the absence of obesity. We implemented successfully a multi-channel flow methodology on ImageStream(X), to image single histone staining (H2A, H2B, H3, H4, macroH2A1.1 and macroH2A1.2). We report here a significant depletion of the levels of histone variants macroH2A1.1 and macroH2A1.2 in the serum of lean MAFLD patients, either individually or in complex with H2B.
In summary, we identified a new circulating histone signature able to discriminate the severity of steatosis in individuals with lean MAFLD, using a rapid and non-invasive ImageStream(X)-based imaging technology.
In summary, we identified a new circulating histone signature able to discriminate the severity of steatosis in individuals with lean MAFLD, using a rapid and non-invasive ImageStream(X)-based imaging technology.
Multiple myeloma (MM) patients with high cytogenetic risk have poor outcomes. In CASTOR, daratumumab plus bortezomib/dexamethasone (D-Vd) prolonged progression-free survival (PFS) versus bortezomib/dexamethasone (Vd) alone and exhibited tolerability in patients with relapsed or refractory MM (RRMM).
This subgroup analysis evaluated D-Vd versus Vd in CASTOR based on cytogenetic risk, determined using fluorescence in situ hybridization and/or karyotype testing performed locally. High-risk patients had t(4;14), t(14;16), and/or del17p abnormalities. Minimal residual disease (MRD; 10
sensitivity threshold) was assessed via the clonoSEQ® assay V2.0. Of the 498 patients randomized, 40 (16%) in the D-Vd group and 35 (14%) in the Vd group were categorized as high risk.
After a median follow-up of 40.0 months, D-Vd prolonged median PFS versus Vd in patients with standard (16.6 vs 6.6 months; HR, 0.26; 95% CI, 0.19-0.37; P < 0.0001) and high (12.6 vs 6.2 months; HR, 0.41; 95% CI, 0.21-0.83; P = 0.0106) cytogenetic risk. D-Vd achieved deep responses, including higher rates of MRD negativity and sustained MRD negativity versus Vd, regardless of cytogenetic risk. The safety profile was consistent with the overall population of CASTOR.
These updated data reinforce the effectiveness and tolerability of daratumumab-based regimens for RRMM, regardless of cytogenetic risk status.
ClinicalTrials.gov, NCT02136134 . Registered 12 May 2014.
ClinicalTrials.gov, NCT02136134 . Registered 12 May 2014.
Read More: https://www.selleckchem.com/products/FK-506-(Tacrolimus).html
|
|
Notes is a web-based application for online taking notes. You can take your notes and share with others people. If you like taking long notes, notes.io is designed for you. To date, over 8,000,000,000+ notes created and continuing...
With notes.io;
- * You can take a note from anywhere and any device with internet connection.
- * You can share the notes in social platforms (YouTube, Facebook, Twitter, instagram etc.).
- * You can quickly share your contents without website, blog and e-mail.
- * You don't need to create any Account to share a note. As you wish you can use quick, easy and best shortened notes with sms, websites, e-mail, or messaging services (WhatsApp, iMessage, Telegram, Signal).
- * Notes.io has fabulous infrastructure design for a short link and allows you to share the note as an easy and understandable link.
Fast: Notes.io is built for speed and performance. You can take a notes quickly and browse your archive.
Easy: Notes.io doesn’t require installation. Just write and share note!
Short: Notes.io’s url just 8 character. You’ll get shorten link of your note when you want to share. (Ex: notes.io/q )
Free: Notes.io works for 14 years and has been free since the day it was started.
You immediately create your first note and start sharing with the ones you wish. If you want to contact us, you can use the following communication channels;
Email: [email protected]
Twitter: http://twitter.com/notesio
Instagram: http://instagram.com/notes.io
Facebook: http://facebook.com/notesio
Regards;
Notes.io Team
